1. |
From the Editor |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 2-2
&NA;,
Preview
|
PDF (1125KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
2. |
MIDAS revisited - perhaps atherosclerosis was not to blame |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 3-4
Gill Higgins,
Preview
|
PDF (2344KB)
|
|
摘要:
There appears to be little agreement regarding the interpretation of data from the Multicentre Isradipine/Diuretic Atherosclerosis Study (MIDAS). While the increase in intima-media thickness (IMT) was significantly lower in isradipine recipients than the diuretic group at 6 months, the subsequent rates of increase were similar in the 2 groups for the remaining follow-up period. Consequently, it has been possible to use the results to argue both for and against the antiatherosclerotic activity of isradipine. But now, Dr Göran Berglund and colleagues from Lund University, Malmö, Sweden, are suggesting that factors other than atherosclerosis may be responsible for the large initial increase in IMT seen in the diuretic group.
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 4-4
&NA;,
Preview
|
PDF (1106KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
4. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 5-5
&NA;,
Preview
|
PDF (1019KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
5. |
DUE ensures appropriate use of IV ciprofloxacin |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 6-6
&NA;,
Preview
|
PDF (1172KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 7-7
&NA;,
Preview
|
PDF (1018KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
7. |
Focus on thymidylate synthase |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 8-8
&NA;,
Preview
|
PDF (1072KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
8. |
HIV protease inhibitors - will they fulfil their promise? |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 9-10
Gill Higgins,
DB Jack,
Preview
|
PDF (2244KB)
|
|
摘要:
The development of HIV protease inhibitors led to renewed hope for an effective anti-AIDS treatment. But problems encountered in early studies of the new agents, such as hepatotoxicity, low oral bioavailability and insufficient potency, hampered the research efforts of several companies. However, perseverance has paid off, and a number of drugs with desirable properties are now undergoing extensive investigations. These include saquinavir, A-84538 and VX-478. At 2 recent conferences on antivirals [see main text for details], several speakers expressed their views on the current status of this class.
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 11-11
&NA;,
Preview
|
PDF (1049KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
10. |
Oral etoposide for refractory and relapsing lymphoma? |
|
Inpharma Weekly,
Volume &NA;,
Issue 971,
1995,
Page 12-12
&NA;,
Preview
|
PDF (1068KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|